- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Bristol-Myers Squibb (BMY)
Assess today's live Bristol-Myers Squibb (BMY) share price, performance and insights using our live NYSE: BMY stock exchange data.
Analyse the historical data and Bristol-Myers Squibb share price performance charts on this page. Our technical summary section provides analysis on Bristol-Myers Squibb share price buy/sell indicators using real-time data (or discuss the Bristol-Myers Squibb (BMY) stock price today with other investors in the Bristol-Myers Squibb NYSE share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NYSE BMY share price (ISIN: US1101221083) to enhance your trading decisions with our free investment tools and resources.
What Is the Bristol-Myers Squibb Share Price Today?
The Bristol-Myers Squibb share price today is 46.86.
What Is the Stock Symbol for Bristol-Myers Squibb
The stock symbol (or 'ticker') for Bristol-Myers Squibb Company is "BMY."
What Stock Exchange Does Bristol-Myers Squibb Trade On?
Bristol-Myers Squibb Company is listed and trades on the NYSE stock exchange.
Is Bristol-Myers Squibb a Good Stock to Buy?
Determining whether Bristol-Myers Squibb Company—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Bristol-Myers Squibb share price performance charts on this page. Our technical summary section provides analysis on Bristol-Myers Squibb share price buy/sell indicators using real-time data (or discuss the Bristol-Myers Squibb (BMY) stock price today with other investors in the Bristol-Myers Squibb NYSE share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NYSE BMY share price (ISIN: US1101221083) to enhance your trading decisions with our free investment tools and resources.
What Is the Bristol-Myers Squibb Share Price Today?
The Bristol-Myers Squibb share price today is 46.86.
What Is the Stock Symbol for Bristol-Myers Squibb
The stock symbol (or 'ticker') for Bristol-Myers Squibb Company is "BMY."
What Stock Exchange Does Bristol-Myers Squibb Trade On?
Bristol-Myers Squibb Company is listed and trades on the NYSE stock exchange.
Is Bristol-Myers Squibb a Good Stock to Buy?
Determining whether Bristol-Myers Squibb Company—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
46.86
+0.02(+0.04%)
Closed·
After Hours
47.00+0.13(+0.28%)
·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
46.72
47.40
52 wk Range
39.35
63.33
BMY Scorecard
Full Analysis
High shareholder yield
Unusual trading volume
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
46.7247.40
52 wk Range
39.3563.33
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(5.29%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(5.29%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BMY Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Neutral
Price Target
57.10
Upside
+21.84%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Has raised its dividend for 3 consecutive years
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of relapsed/refractory multiple myeloma; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Reblozyl to treat anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Cobenfy to treat schizophrenia in adults; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; and Abraxane for the treatment of breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
Bristol-Myers Squibb Company SWOT Analysis
Pipeline Potential | Explore BMY's promising drug candidates, including Cobenfy for schizophrenia and Arlo-cel for multiple myeloma, poised to address unmet medical needs |
Market Challenges | Delve into BMY's strategies to navigate patent expirations, generic competition, and intense rivalry in key therapeutic areas like oncology |
Financial Resilience | BMY's strong fundamentals, with $47.64B in revenue and 74.69% gross margin, support its 5.29% dividend yield and 55-year dividend streak |
Analyst Outlook | Price targets range from $43 to $62, reflecting varied perspectives on BMY's growth potential amid product launches and market uncertainties |
Bristol-Myers Squibb Company Earnings Call Summary for Q1/2025
- Q1 2025 EPS of $1.80 surpassed $1.52 forecast; revenue reached $11.2B, exceeding $10.68B estimate
- Growth portfolio sales up 18%; company raised full-year revenue guidance to $45.8-$46.8B
- Stock dipped 0.72% pre-market despite earnings beat; analysts' price targets range from $36 to $70
- CEO emphasized strong growth portfolio performance, advancing pipeline, and focus on business development
- Company projects non-GAAP EPS of $6.70-$7.00 for 2025; aims for $2B annual cost savings by 2027
Last Updated: 24/04/2025, 15:08
Read Full TranscriptCompare BMY to Peers and Sector
Metrics to compare | BMY | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBMYPeersSector | |
|---|---|---|---|---|
P/E Ratio | 17.6x | 15.8x | −0.5x | |
PEG Ratio | 0.09 | −0.07 | 0.00 | |
Price/Book | 5.5x | 1.6x | 2.6x | |
Price / LTM Sales | 2.0x | 2.8x | 3.0x | |
Upside (Analyst Target) | 18.4% | 204.6% | 52.4% | |
Fair Value Upside | Unlock | 30.6% | 8.7% | Unlock |
Analyst Ratings
8 Buy
18 Hold
1 Sell
Ratings:
27 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 57.10
(+21.84% Upside)
Earnings
Latest Release
Apr 24, 2025
EPS / Forecast
1.80 / 1.52
Revenue / Forecast
11.20B / 10.68B
People Also Watch
FAQ
What Is the Bristol-Myers Squibb (BMY) Share Price Today?
The live Bristol-Myers Squibb share price today is 46.86.
What Stock Exchange Does Bristol-Myers Squibb (BMY) Trade On?
Bristol-Myers Squibb is listed and trades on the New York Stock Exchange stock exchange.
What Is the Ticker (Stock Symbol) for Bristol-Myers Squibb?
The stock symbol (also called a 'ticker') for Bristol-Myers Squibb is "BMY."
Does Bristol-Myers Squibb Pay Dividends? What’s The Current BMY Dividend Yield?
Yes, BMY Pays Dividends to its Shareholders. The current Bristol-Myers Squibb dividend yield is 5.29%.
What Is the Current Bristol-Myers Squibb Market Cap?
As of today, Bristol-Myers Squibb market capitalisation is 95.36B.
What Is Bristol-Myers Squibb's (BMY) Earnings Per Share (TTM)?
The Bristol-Myers Squibb EPS 2.67 (Trailing Twelve Months).
When Is the Next Bristol-Myers Squibb Earnings Date?
Bristol-Myers Squibb's next earnings report will be released on 30 Jul 2025.
Is BMY a Buy or Sell From a Technical Analyst Perspective?
Based on today's Bristol-Myers Squibb moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Bristol-Myers Squibb Stock Split?
Bristol-Myers Squibb has split 5 times. (See the BMY stock split history page for full effective split date and price information.)
How Many Employees Does Bristol-Myers Squibb Have?
Bristol-Myers Squibb currently has 34100 employees.
What is the current trading status of Bristol-Myers Squibb (BMY)?
As of 22 Jun 2025, Bristol-Myers Squibb (BMY) is trading at a price of 46.86, with a previous close of 46.84. The stock has fluctuated within a day range of 46.72 to 47.40, while its 52-week range spans from 39.35 to 63.33.
What Is Bristol-Myers Squibb (BMY) Price Target According to Analysts?
The average 12-month price target for Bristol-Myers Squibb is USD57.09591, with a high estimate of USD68 and a low estimate of USD36. 8 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Neutral. The stock has an +21.84% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.